Premium
CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP
Author(s) -
Kuruvilla J.,
Crump M.,
Villa D.,
Aslam M.,
Prica A.,
Scott D.W.,
AbdelSamad N.,
Couban S.,
Doucet S.,
Dudebout J.,
Fleury I.,
Fraser G.,
Larouche J.,
Shafey M.,
Skrabek P.,
Skamene T.,
Winch C.,
Shepherd L.,
Chen B.E.,
Hay A.E.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_76
Subject(s) - medicine , rituximab , salvage therapy , interim analysis , oncology , clinical endpoint , gemcitabine , febrile neutropenia , diffuse large b cell lymphoma , population , neutropenia , ibrutinib , chemotherapy regimen , surgery , chemotherapy , randomized controlled trial , lymphoma , leukemia , environmental health , chronic lymphocytic leukemia